SE445466B - Sett att foroka rotavirus in vitro - Google Patents
Sett att foroka rotavirus in vitroInfo
- Publication number
- SE445466B SE445466B SE7812283A SE7812283A SE445466B SE 445466 B SE445466 B SE 445466B SE 7812283 A SE7812283 A SE 7812283A SE 7812283 A SE7812283 A SE 7812283A SE 445466 B SE445466 B SE 445466B
- Authority
- SE
- Sweden
- Prior art keywords
- cells
- virus
- medium
- serum
- trypsin
- Prior art date
Links
- 241000702670 Rotavirus Species 0.000 title claims description 11
- 238000000338 in vitro Methods 0.000 title claims description 4
- 241000700605 Viruses Species 0.000 claims description 38
- 210000004027 cell Anatomy 0.000 claims description 34
- 239000002609 medium Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- 108090000631 Trypsin Proteins 0.000 claims description 17
- 102000004142 Trypsin Human genes 0.000 claims description 17
- 239000012588 trypsin Substances 0.000 claims description 16
- 229960001322 trypsin Drugs 0.000 claims description 16
- 238000004113 cell culture Methods 0.000 claims description 11
- 244000309466 calf Species 0.000 claims description 10
- 210000003292 kidney cell Anatomy 0.000 claims description 8
- 241000282693 Cercopithecidae Species 0.000 claims description 6
- 102000035195 Peptidases Human genes 0.000 claims description 6
- 108091005804 Peptidases Proteins 0.000 claims description 6
- 239000012679 serum free medium Substances 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 229940088598 enzyme Drugs 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 239000004365 Protease Substances 0.000 claims description 3
- 210000003501 vero cell Anatomy 0.000 claims description 3
- 108010004032 Bromelains Proteins 0.000 claims description 2
- 108090000317 Chymotrypsin Proteins 0.000 claims description 2
- 108010019160 Pancreatin Proteins 0.000 claims description 2
- 108090000787 Subtilisin Proteins 0.000 claims description 2
- 235000019835 bromelain Nutrition 0.000 claims description 2
- 229960002376 chymotrypsin Drugs 0.000 claims description 2
- 229940055695 pancreatin Drugs 0.000 claims description 2
- -1 éronase Proteins 0.000 claims description 2
- 230000014759 maintenance of location Effects 0.000 claims 1
- 230000001902 propagating effect Effects 0.000 claims 1
- 230000002797 proteolythic effect Effects 0.000 claims 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 229930182555 Penicillin Natural products 0.000 description 6
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical group N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 6
- 230000000120 cytopathologic effect Effects 0.000 description 6
- 229940049954 penicillin Drugs 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical group CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 239000007640 basal medium Substances 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 3
- 238000001493 electron microscopy Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010017913 Gastroenteritis rotavirus Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 101710151387 Serine protease 1 Proteins 0.000 description 1
- 102100032491 Serine protease 1 Human genes 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 101710119665 Trypsin-1 Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009739 binding Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000011072 cell harvest Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12361—Methods of inactivation or attenuation
- C12N2720/12364—Methods of inactivation or attenuation by serial passage
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB5009477 | 1977-12-01 | ||
| GB5390677 | 1977-12-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE7812283L SE7812283L (sv) | 1979-06-02 |
| SE445466B true SE445466B (sv) | 1986-06-23 |
Family
ID=26266615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE7812283A SE445466B (sv) | 1977-12-01 | 1978-11-29 | Sett att foroka rotavirus in vitro |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US4205131A (en, 2012) |
| JP (1) | JPS5495789A (en, 2012) |
| CH (1) | CH646194A5 (en, 2012) |
| DE (1) | DE2851928A1 (en, 2012) |
| DK (1) | DK152516C (en, 2012) |
| FI (1) | FI63060C (en, 2012) |
| FR (1) | FR2410675A1 (en, 2012) |
| GB (1) | GB2009786A (en, 2012) |
| NL (1) | NL191183C (en, 2012) |
| SE (1) | SE445466B (en, 2012) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4500513A (en) * | 1979-05-15 | 1985-02-19 | Miles Laboratories, Inc. | Influenza vaccine production in liquid cell culture |
| USRE33164E (en) * | 1979-05-15 | 1990-02-13 | Mobay Corporation | Influenza vaccine production in liquid cell culture |
| US4624850A (en) * | 1984-02-09 | 1986-11-25 | Royal Children's Hospital Research Foundation | Live attenuated human rotavirus vaccine |
| US4636385A (en) * | 1985-02-15 | 1987-01-13 | The Wistar Institute Of Anatomy & Biology | Vaccine, method for its preparation, and use thereof in vaccinating humans against rotavirus infection |
| US5626851A (en) * | 1987-11-30 | 1997-05-06 | The Wistar Institute Of Anatomy And Biology | Rotavirus reassortant vaccine |
| US5147639A (en) * | 1990-06-19 | 1992-09-15 | Ambico, Inc. | Type-c rotavirus cultures and uses therefor |
| US5610049A (en) * | 1991-05-01 | 1997-03-11 | The Wistar Institute Of Anatomy And Biology | Human rotavirus HCR3A and method of growing said rotavirus |
| ES2323490T3 (es) * | 1994-11-10 | 2009-07-17 | Baxter Healthcare Sa | Procedimiento de produccion de agentes biologicos en un medio de cultivo sin proteinas. |
| US6146873A (en) * | 1994-11-10 | 2000-11-14 | Baxter Aktiengesellschaft | Production of orthomyxoviruses in monkey kidney cells using protein-free media |
| US5698433A (en) * | 1994-11-10 | 1997-12-16 | Immuno Ag | Method for producing influenza virus and vaccine |
| US5753489A (en) * | 1994-11-10 | 1998-05-19 | Immuno Ag | Method for producing viruses and vaccines in serum-free culture |
| US5756341A (en) * | 1994-11-10 | 1998-05-26 | Immuno Ag | Method for controlling the infectivity of viruses |
| KR19990072201A (ko) * | 1996-10-18 | 1999-09-27 | 무타이 마사히꼬 | 로타바이러스 항원, 로타바이러스 감염증에 대한백신 및 진단제와 항원 제조방법 |
| US6110461A (en) * | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
| US6656719B1 (en) * | 1997-10-27 | 2003-12-02 | Merck & Co., Inc. | Serum-free, low-protein media for rotavirus vaccine production |
| FR2801900B1 (fr) * | 1999-12-03 | 2004-02-27 | Pasteur Merieux Serums Vacc | Methode de production de cellules animales adherentes |
| US6830917B2 (en) * | 2001-12-10 | 2004-12-14 | Baxter Healthcare S.A. | Method of isolation and purification of trypsin from pronase protease and use thereof |
| DK1984007T3 (en) * | 2006-02-13 | 2015-12-07 | Oncolytics Biotech Inc | Application of Low-dose local immunosuppression for amplification of viral oncolytic therapy |
| AU2007251122B2 (en) * | 2006-05-12 | 2013-01-10 | Bharat Biotech International Limited | A composition useful as a vaccine |
| CN117070475B (zh) * | 2023-10-13 | 2023-12-29 | 金宇保灵生物药品有限公司 | 牛轮状病毒无血清悬浮培养方法及其产品和应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1539221A (en) * | 1976-09-30 | 1979-01-31 | Wellcome Found | Viral preparations |
-
1978
- 1978-11-29 SE SE7812283A patent/SE445466B/sv not_active IP Right Cessation
- 1978-11-30 FR FR7833793A patent/FR2410675A1/fr active Granted
- 1978-11-30 GB GB7846602A patent/GB2009786A/en not_active Expired - Lifetime
- 1978-11-30 CH CH1226878A patent/CH646194A5/de not_active IP Right Cessation
- 1978-11-30 DK DK542878A patent/DK152516C/da not_active IP Right Cessation
- 1978-11-30 FI FI783663A patent/FI63060C/fi not_active IP Right Cessation
- 1978-11-30 DE DE19782851928 patent/DE2851928A1/de active Granted
- 1978-11-30 JP JP14855678A patent/JPS5495789A/ja active Granted
- 1978-11-30 NL NL7811763A patent/NL191183C/xx not_active IP Right Cessation
- 1978-11-30 US US05/965,045 patent/US4205131A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| NL191183C (nl) | 1995-03-01 |
| FI63060C (fi) | 1983-04-11 |
| FI63060B (fi) | 1982-12-31 |
| DE2851928C2 (en, 2012) | 1987-06-04 |
| DK542878A (da) | 1979-06-02 |
| NL191183B (nl) | 1994-10-03 |
| CH646194A5 (de) | 1984-11-15 |
| DK152516B (da) | 1988-03-07 |
| DE2851928A1 (de) | 1979-06-21 |
| SE7812283L (sv) | 1979-06-02 |
| FI783663A7 (fi) | 1979-06-02 |
| US4205131A (en) | 1980-05-27 |
| JPS6150599B2 (en, 2012) | 1986-11-05 |
| NL7811763A (nl) | 1979-06-06 |
| FR2410675A1 (fr) | 1979-06-29 |
| DK152516C (da) | 1988-08-01 |
| GB2009786A (en) | 1979-06-20 |
| JPS5495789A (en) | 1979-07-28 |
| FR2410675B1 (en, 2012) | 1983-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE445466B (sv) | Sett att foroka rotavirus in vitro | |
| JP5264843B2 (ja) | 細胞培養におけるインフルエンザウイルスの複製の方法、および本方法によって入手可能なインフルエンザウイルス | |
| Fishman | Antibody formation in vitro | |
| Fraser et al. | Increased tendency to spontaneous in-vitro lymphocyte transformation in clinically active multiple sclerosis | |
| Doyle et al. | Interactions between viruses and lymphocytes: I. In vivo replication of lymphocytic choriomeningitis virus in mononuclear cells during both chronic and acute viral infections | |
| Curnow | In vitro Agglutination of Bovine Erythrocytes infected with Babesia argentine | |
| US5071758A (en) | Production of cell strains capable of propagating respiratory syncytial virus, compositions containing such virus and their use in diagnosis of respiratory syncytial virus infection | |
| US3699222A (en) | Production of viral interfering substances | |
| Boyer | Chorioallantoic membrane lesions produced by inoculation of adult fowl leucocytes | |
| Lee et al. | Characterization of the blastogenic and cytotoxic responses of normal mice to ecotropic C-type viral gp71 | |
| Mogensen et al. | Role of activated macrophages in resistance of congenitally athymic nude mice to hepatitis induced by herpes simplex virus type 2 | |
| CA1162147A (en) | Feline vaccines | |
| Manaker et al. | Long-term propagation of a murine leukemia virus in an established cell line | |
| Cihak et al. | Immunological tolerance to lymphocytic choriomeningitis virus in neonatally infected virus carrier mice: evidence supporting a clonal inactivation mechanism | |
| Blaškovič et al. | Experimental infection of weanling pigs with A/Swine influenza virus: 2. The shedding of virus by infected animals | |
| Yaffe et al. | The distribution and in vitro propagation of an agent causing high plasma lactic dehydrogenase activity | |
| Howell et al. | In vivo and in vitro studies of the effects of immune rat serum on Fasciola hepatica | |
| Furukawa et al. | Studies on Hemagglutination by Rubella Virus. | |
| Karpas et al. | Sinus histiocytosis with massive lymphadenopathy: virological, immunological and morphological studies | |
| Blasecki et al. | Restoration of specific immunity against SV40 tumor‐specific transplantation antigen to lymphoid cells from tumor‐bearing mice | |
| Li et al. | Serum neutralization tests in mice and in tissue culture against three types of poliomyelitis virus | |
| US3432595A (en) | Melanoma cell line of canine origin,its propagation and use,and vaccines derived therefrom | |
| Labzoffsky et al. | Isolation of a haemadsorption virus from the recent outbreak of respiratory illness in Ontario | |
| Tevethia et al. | The effect of phleomycin on the replication of papovavirus SV40 and other DNA viruses in simian cells | |
| Shichinohe et al. | On the interrelationship between virus concentration and pathological changes of pancreas in mice induced by EMC-virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NAL | Patent in force |
Ref document number: 7812283-5 Format of ref document f/p: F |
|
| NUG | Patent has lapsed |
Ref document number: 7812283-5 Format of ref document f/p: F |